Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Pathology

• Publication date

  2001-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0002-9440(10)61715-4PMID 11485902PMCID PMC1850561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice

  2001cited by this paper
• Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

  2001cited by this paper
• Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

  2001cited by this paper
• Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization.

  2000cited by this paper
• Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

  2000cited by this paper
• Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000cited by this paper
• Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease

  2000influential reference
• In vivo reversal of amyloid-beta lesions in rat brain.

  2000cited by this paper
• High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

  2000cited by this paper
• A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

  2000cited by this paper
• Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

  2000cited by this paper
• The Pathogenesis of Alzheimer's Disease: Is Amyloid β‐Protein the Beginning or the End?

  2000cited by this paper
• Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain

  2000cited by this paper
• Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease

  2000cited by this paper
• Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein

  2000cited by this paper
• A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

  2000cited by this paper
• Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.

  2000cited by this paper
• Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease

  2000cited by this paper
• In Vivo Reversal of Amyloid‐β Lesions in Rat Brain

  2000cited by this paper
• Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

  2000cited by this paper
• Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

  2000cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Recognition Sequence Design for Peptidyl Modulators of ‚-Amyloid Aggregation

  1999cited by this paper
• Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity.

  1999cited by this paper
• Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.

  1999cited by this paper
• Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias.

  1999cited by this paper
• Increased plasma amyloid beta protein 1-42 levels in Down syndrome.

  1998cited by this paper
• Increased plasma amyloid β protein 1–42 levels in Down syndrome

  1998cited by this paper
• Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

  1998cited by this paper
• Cerebrovascular Accumulation and Increased Blood‐Brain Barrier Permeability to Circulating Alzheimer's Amyloid β Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy

  1998cited by this paper
• β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy

  1998cited by this paper
• Antibodies directed to the carboxyl terminus of amyloid β-peptide recognize sequence epitopes and distinct immunoreactive deposits in Alzheimer's disease brain

  1998cited by this paper
• Disaggregation of Alzheimer β-amyloid by site-directed mAb

  1997cited by this paper
• Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology.

  1997cited by this paper
• Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

  1997cited by this paper
• Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier.

  1997cited by this paper
• Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects.

  1997cited by this paper
• Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats.

  1996cited by this paper
• Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.

  1996cited by this paper
• Alzheimer's β‐amyloid peptide is conformationally modified by apolipoprotein E in vitro

  1996cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid β in guinea pigs

  1996cited by this paper
• Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs.

  1996cited by this paper
• Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure

  1995cited by this paper
• Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain.

  1994cited by this paper
• Passage of human amyloid β-protein 1–40 across the murine blood-brain barrier

  1994cited by this paper
• Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier.

  1994cited by this paper
• Demonstration of poly-N-acetyl lactosamine residues in ameboid and ramified microglial cells in rat brain by tomato lectin binding.

  1994cited by this paper
• The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease.

  1993cited by this paper
• Cerebrospinal fluid inhibits Alzheimer β‐amyloid fibril formation in vitro

  1993cited by this paper
• Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution

  1993cited by this paper
• Blood-brain barrier transport of circulating Alzheimer's amyloid beta.

  1993cited by this paper
• Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: a practical guide.

  1992cited by this paper
• In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity.

  1991cited by this paper
• Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.

  1991cited by this paper
• In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity ☆

  1991cited by this paper
• Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease.

  1989cited by this paper
• The antigenic index: a novel algorithm for predicting antigenic determinants

  1988cited by this paper
• Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3.

  1986cited by this paper
• Fact and Speculation on the Function of Immune Response Genes in Antigen Presentation

  1981cited by this paper

• Spontaneous and Drug-Induced Amyloid-Related Imaging Abnormalities: Overlaps, Divergences, and Clinical Implications Across a Continuum Between Alzheimer’s Disease and Cerebral Amyloid Angiopathy

  2026cites this paper
• β-Amyloids and Immune Responses Associated with Alzheimer’s Disease

  2024cites this paper
• Lessons from antiamyloid-β immunotherapies in Alzheimer's disease.

  2023cites this paper
• Attempts to Develop Vaccines Against Alzheimer’s Disease: A Systematic Review of Ongoing and Completed Vaccination Trials in Humans

  2023cites this paper
• Amyloid-β targeting immunisation in aged non-human primate (Microcebus murinus)

  2022cites this paper
• Dysfunction of the Blood-Brain Barrier—A Key Step in Neurodegeneration and Dementia

  2020cites this paper
• Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease

  2020cites this paper
• The Role of Neurovascular System in Neurodegenerative Diseases

  2020cites this paper
• Promising Molecular Targets for Pharmacological Therapy of Neurodegenerative Pathologies

  2020cites this paper
• Immunotherapy in Alzheimer’s Disease

  2019cites this paper
• Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer’s Disease

  2019cites this paper
• Current and emerging avenues for Alzheimer's disease drug targets

  2019cites this paper
• The mechanism of action of clioquinol for the treatment of Alzheimer's disease

  2018cites this paper
• Microglia phenotypes in aging-associated diseases

  2017cites this paper
• AMYLOD BETAPEPTIDE PROTOFIBRLS AND USES THEREOF

  2017cites this paper
• Amyloid beta: structure, biology and structure-based therapeutic development

  2017cites this paper
• The Aged Dog as a Natural Model of Alzheimer’s Disease Progression

  2017cites this paper
• Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice

  2017cites this paper
• Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis.

  2017cites this paper
• Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves 18FDG retention in 5XFAD mouse model of Alzheimer's disease.

  2017cites this paper
• Canine and Feline Dementia

  2017cites this paper
• Non human primate models for Alzheimer’s disease-related research and drug discovery

  2017cites this paper
• Influence of ApoE on LRP1 Function and Amyloid Transport Across the Blood-Brain Barrier

  2016cites this paper
• Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice

  2016cites this paper
• Developing therapeutic vaccines against Alzheimer’s disease

  2016cites this paper
• Immunotherapeutic approaches for Alzheimer's disease.

  2015cites this paper
• Functional implications of tau-fyn interactions in Alzheimer's disease

  2015cites this paper
• Engineering of Affibody molecules targeting the Alzheimer’s-related amyloid β peptide

  2015cites this paper
• Central nervous system myeloid cells as drug targets: current status and translational challenges

  2015cites this paper
• Aging Mechanisms

  2015cites this paper
• Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.

  2015cites this paper
• Papel regulador de la proteína priónica celular en la enfermedad de Alzheimer y uso de gamma-péptidos como potenciales agentes terapéuticos

  2015cites this paper
• Immunotherapeutic Approaches Against Amyloid-β in Drug Discovery for Alzheimer’s Disease

  2015cites this paper
• Alzheimer’s Disease and Mechanism-Based Attempts to Enhance Cognition

  2015cites this paper
• Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases

  2015cites this paper
• Bacteriophage--a common divergent therapeutic approach for Alzheimer's disease and type II diabetes mellitus.

  2014cites this paper
• Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation

  2014cites this paper
• Immunotherapy for Alzheimer's disease.

  2014cites this paper
• C URRENT OPINION Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

  2014cites this paper
• Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

  2014cites this paper
• Stem‐Cell Challenges in the Treatment of Alzheimer's Disease: A Long Way from Bench to Bedside

  2014cites this paper
• Novel immunological approaches for the treatment of Alzheimer's disease.

  2014cites this paper
• Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

  2014cites this paper
• Peptide Vaccine for Alzheimer's Disease

  2013cites this paper
• Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance*

  2013cites this paper
• Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies.

  2013cites this paper
• Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice.

  2013cites this paper
• T‐cell epitope‐dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice

  2013cites this paper
• Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients

  2013cites this paper
• Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.

  2013cites this paper
• Chronological Primacy ofOxidative-Induced Neuronal Damage in thePathogenesis of Alzheimer'sDisease

  2013cites this paper
• CD4 T cells in immunity and immunotherapy of Alzheimer's disease

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• MER5101, a Novel Aβ1-15:DT Conjugate Vaccine, Generates a Robust Anti-Aβ Antibody Response and Attenuates Aβ Pathology and Cognitive Deficits in APPswe/PS1ΔE9 Transgenic Mice

  2013cites this paper
• Chronological Primacy of Oxidative-Induced Neuronal Damage in the Pathogenesis of Alzheimer's Disease

  2013cites this paper
• Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging

  2013cites this paper
• Altered Serum IgG Levels to α-Synuclein in Dementia with Lewy Bodies and Alzheimer’s Disease

  2013cites this paper
• Current Conceptual View of Alzheimer’s Disease

  2012cites this paper
• Novel Detox Gel Depot Sequesters β-Amyloid Peptides in a Mouse Model of Alzheimer’s Disease

  2012cites this paper
• The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update

  2012cites this paper
• transgenic mouse models used in drug discovery for Alzheimer's disease: an update

  2012cites this paper
• Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice

  2012cites this paper
• The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization.

  2012cites this paper
• Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue.

  2012cites this paper
• Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

  2012cites this paper
• Strategies for Inhibiting Protein Aggregation: Therapeutic Approaches to Protein-Aggregation Diseases

  2012cites this paper
• Characterising transgenic APP mutation mouse models of amyloid pathology for use in preclinical immunotherapy

  2012cites this paper
• Aging and dementia : Clinical relevance of early markers and late interventions

  2012cites this paper
• Immunotherapy for Tauopathies

  2011cites this paper
• BDNF Plasma Level als Marker für Alzheimer in der VITA- Studie

  2011cites this paper
• Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders

  2011cites this paper
• Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

  2011cites this paper
• Stem cell therapy for Alzheimer's disease.

  2011cites this paper
• Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging

  2011cites this paper
• Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab.

  2011cites this paper
• Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats.

  2011cites this paper
• Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice.

  2011cites this paper
• Antibody-based therapy in Alzheimer's disease

  2011cites this paper
• Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

  2011influential citation
• Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.

  2011cites this paper
• Identification of the shortest Aβ-peptide generating highly specific antibodies against the C-terminal end of amyloid-β42.

  2011cites this paper
• Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models

  2010influential citation
• Amyloid-beta immunotherapy for Alzheimer's disease.

  2010cites this paper
• AFFITOME® technology in neurodegenerative diseases: The doubling advantage

  2010cites this paper
• Vaccination as a therapeutic approach to Alzheimer's disease.

  2010cites this paper
• Simplified β-amyloid peptides for safer Alzheimer’s vaccines development

  2010cites this paper
• Diminished A β Burden in Tg2576 Mice Following a Prophylactic Oral Immunization with a Salmonella-based A β Derivative Vaccine

  2010influential citation
• Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis

  2010cites this paper
• Why Alzheimer's Disease Starts with a Memory Impairment: Neurophysiological Insight

  2010cites this paper
• Design and development of non-fibrillar amyloid beta as a potential Alzheimer vaccine.

  2010cites this paper
• APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks.

  2010cites this paper
• Murine models of Alzheimer's disease and their use in developing immunotherapies.

  2010cites this paper
• Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?

  2010cites this paper
• Amyloid-β Immunotherapy for Alzheimers Disease

  2010cites this paper
• Peptide classification using optimal and information theoretic syntactic modeling

  2010cites this paper
• Immunotherapy for Alzheimer's disease.

  2010cites this paper
• Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

  2010cites this paper
• Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications

  2010cites this paper
• Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy

  2010cites this paper
• Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

  2010cites this paper